Novolog (NVLG) Q4 2024 earnings summary

Executive summary

• Achieved strong revenue growth in 2024, with total revenues reaching ₪2,021.6 million, a 23% increase year-over-year.

• Adjusted EBITDA rose by 32% to ₪112.1 million, reflecting operational improvements.

• Net income for 2024 was ₪41 million, with a gross profit of ₪180.8 million.

• Maintained a robust balance sheet with ₪248 million in cash and no debt.

• Continued focus on innovation, operational efficiency, and customer-centric growth.

Financial highlights

• Revenue increased by 23% year-over-year to ₪2,021.6 million.

• Gross profit grew by 7% to ₪180.8 million.

• Adjusted EBITDA (excluding non-operational items) reached ₪142.8 million, up 26%.

• Net income for the year was ₪41 million.

• Dividend distribution policy set at 70% of net profit, with ₪32 million paid in 2024.

Outlook and guidance

• Strategic focus on organic growth, operational efficiency, and digital health innovation.

• Plans to continue investments in technology and potential acquisitions to support long-term growth.